Vaccines for mucosal immunity to combat emerging infectious diseases.

F W van Ginkel, H H Nguyen, J R McGhee
Author Information
  1. F W van Ginkel: Department of Microbiology, University of Alabama at Birmingham, 35294, USA. fritsv@micro.microbio.uab.edu

Abstract

The mucosal immune system consists of molecules, cells, and organized lymphoid structures intended to provide immunity to pathogens that impinge upon mucosal surfaces. Mucosal infection by intracellular pathogens results in the induction of cell- mediated immunity, as manifested by CD4-positive (CD4 + ) T helper-type 1 cells, as well as CD8 + cytotoxic T-lymphocytes. These responses are normally accompanied by the synthesis of secretory immunoglobulin A (S-IgA) antibodies, which provide an important first line of defense against invasion of deeper tissues by these pathogens. New-generation live, attenuated viral vaccines, such as the cold-adapted, recombinant nasal influenza and oral rotavirus vaccines, optimize this form of mucosal immune protection. Despite these advances, new and reemerging infectious diseases are tipping the balance in favor of the parasite; continued mucosal vaccine development will be needed to effectively combat these new threats.

References

  1. Science. 1981 Apr 24;212(4493):471-2 [PMID: 6259737]
  2. Immunity. 1998 Jun;8(6):683-91 [PMID: 9655482]
  3. J Exp Med. 1985 Jan 1;161(1):198-209 [PMID: 2981953]
  4. J Virol. 1989 Aug;63(8):3507-12 [PMID: 2545920]
  5. Proc Natl Acad Sci U S A. 1990 May;87(10):3962-6 [PMID: 2339132]
  6. J Immunol. 1990 Oct 1;145(7):2057-63 [PMID: 1975822]
  7. J Virol. 1990 Dec;64(12):6325-8 [PMID: 1978734]
  8. J Virol. 1991 Mar;65(3):1318-24 [PMID: 1847457]
  9. J Clin Invest. 1991 Jul;88(1):248-52 [PMID: 2056119]
  10. J Immunol. 1992 Jun 15;148(12):3830-6 [PMID: 1602131]
  11. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6901-5 [PMID: 1323121]
  12. J Exp Med. 1993 Feb 1;177(2):475-82 [PMID: 8426116]
  13. Gastroenterology. 1993 Mar;104(3):698-708 [PMID: 8440430]
  14. J Immunol. 1993 Jun 15;150(12):5494-500 [PMID: 7685796]
  15. J Exp Med. 1993 Oct 1;178(4):1309-20 [PMID: 8376936]
  16. J Immunol. 1994 Jan 1;152(1):72-6 [PMID: 8254208]
  17. Semin Immunol. 1993 Dec;5(6):421-30 [PMID: 7907233]
  18. Annu Rev Immunol. 1994;12:63-84 [PMID: 8011293]
  19. J Clin Invest. 1994 Jul;94(1):97-104 [PMID: 7518836]
  20. J Immunol. 1995 Apr 1;154(7):3156-61 [PMID: 7897205]
  21. Eur J Immunol. 1995 Mar;25(3):708-16 [PMID: 7705400]
  22. Adv Exp Med Biol. 1995;371B:1587-90 [PMID: 7502861]
  23. J Immunol. 1996 Feb 15;156(4):1504-14 [PMID: 8568254]
  24. J Infect Dis. 1996 Jun;173(6):1313-9 [PMID: 8648202]
  25. Cell. 1996 Aug 9;86(3):345-8 [PMID: 8756716]
  26. J Immunol. 1998 Oct 15;161(8):4406-10 [PMID: 9780219]
  27. J Immunol. 1998 Dec 1;161(11):6433-8 [PMID: 9834136]
  28. Emerg Infect Dis. 1999 May-Jun;5(3):395-403 [PMID: 10341176]
  29. Sci Am. 1999 Jul;281(1):50-7 [PMID: 10396782]
  30. MMWR Morb Mortal Wkly Rep. 1999 Jul 30;48(29):621-9 [PMID: 10458535]
  31. J Exp Med. 1996 Nov 1;184(5):1879-90 [PMID: 8920875]
  32. J Exp Med. 1997 Jan 20;185(2):293-303 [PMID: 9016878]
  33. J Virol. 1997 Apr;71(4):3120-8 [PMID: 9060675]
  34. Virology. 1997 Mar 3;229(1):143-54 [PMID: 9123856]
  35. J Clin Invest. 1997 Apr 1;99(7):1472-7 [PMID: 9119989]
  36. Science. 1997 Aug 15;277(5328):949-52 [PMID: 9252325]
  37. J Exp Med. 1984 Sep 1;160(3):941-6 [PMID: 6332171]

Grants

  1. AI 18958/NIAID NIH HHS
  2. AI 43197/NIAID NIH HHS
  3. P30 DK 54781/NIDDK NIH HHS

MeSH Term

B-Lymphocytes
Communicable Disease Control
Cytokines
Humans
Immunity, Cellular
Immunity, Mucosal
Immunoglobulin A, Secretory
T-Lymphocytes
T-Lymphocytes, Cytotoxic
Vaccines

Chemicals

Cytokines
Immunoglobulin A, Secretory
Vaccines

Word Cloud

Created with Highcharts 10.0.0mucosalimmunitypathogensimmunecellsprovide+vaccinesnewinfectiousdiseasescombatsystemconsistsmoleculesorganizedlymphoidstructuresintendedimpingeuponsurfacesMucosalinfectionintracellularresultsinductioncell-mediatedmanifestedCD4-positiveCD4Thelper-type1wellCD8cytotoxicT-lymphocytesresponsesnormallyaccompaniedsynthesissecretoryimmunoglobulinS-IgAantibodiesimportantfirstlinedefenseinvasiondeepertissuesNew-generationliveattenuatedviralcold-adaptedrecombinantnasalinfluenzaoralrotavirusoptimizeformprotectionDespiteadvancesreemergingtippingbalancefavorparasitecontinuedvaccinedevelopmentwillneededeffectivelythreatsVaccinesemerging

Similar Articles

Cited By